nVerses Capital LLC Takes $219,000 Position in Guardant Health, Inc. (NASDAQ:GH)

nVerses Capital LLC purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 7,600 shares of the company’s stock, valued at approximately $219,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GH. Vanguard Group Inc. lifted its stake in Guardant Health by 2.7% in the first quarter. Vanguard Group Inc. now owns 11,436,026 shares of the company’s stock valued at $235,925,000 after buying an additional 305,372 shares during the last quarter. Baillie Gifford & Co. boosted its stake in Guardant Health by 0.9% during the 1st quarter. Baillie Gifford & Co. now owns 6,232,104 shares of the company’s stock worth $128,568,000 after purchasing an additional 53,292 shares during the period. Capital International Investors grew its position in Guardant Health by 36.7% during the 4th quarter. Capital International Investors now owns 4,001,803 shares of the company’s stock worth $108,249,000 after purchasing an additional 1,074,452 shares during the last quarter. Eventide Asset Management LLC increased its stake in Guardant Health by 8.3% in the fourth quarter. Eventide Asset Management LLC now owns 3,888,146 shares of the company’s stock valued at $105,174,000 after purchasing an additional 298,616 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Guardant Health by 31.8% in the second quarter. Bank of New York Mellon Corp now owns 1,280,221 shares of the company’s stock valued at $36,973,000 after buying an additional 309,157 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on GH shares. Citigroup boosted their price target on Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Guggenheim upgraded Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price target for the company in a research note on Friday, June 28th. Stephens reiterated an “overweight” rating and issued a $44.00 price objective on shares of Guardant Health in a research report on Friday, May 24th. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, June 4th. Finally, UBS Group lifted their target price on shares of Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 21st. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $39.31.

Guardant Health Trading Down 1.3 %

Shares of GH opened at $25.58 on Monday. The firm’s 50-day moving average is $29.98 and its two-hundred day moving average is $24.62. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $41.06. The company has a current ratio of 6.40, a quick ratio of 6.07 and a debt-to-equity ratio of 16.70. The firm has a market capitalization of $3.15 billion, a P/E ratio of -6.53 and a beta of 1.13.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The firm had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The business’s revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.67) EPS. On average, research analysts predict that Guardant Health, Inc. will post -3.29 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.